

27 March 2026

ASX Announcement

Registration Agreement and Approval of Nasodine in Indonesia

- Nasodine Nasal Spray (“Nasodine”) has been approved for importation and distribution in Indonesia
- With a population of around 285 million, Indonesia is the largest market in Southeast Asia and the 4th most populous country in the world
- This is the first regulatory approval for Nasodine
- Under the Product Registration Services Agreement now executed with PT Pyridam Farma Tbk, Firebrick can access the approval and is entitled to commence importation and distribution of Nasodine Nasal Spray in Indonesia

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) is very pleased to announce that Nasodine Nasal Spray (“**Nasodine**”) has been approved by the Indonesian Government as an ‘antiseptic’ product within the ‘Household Health Supplies’ category. The approval allows importation and marketing of Nasodine Nasal Spray in Indonesia, effective immediately.

The approval follows submission of a technical dossier to the Ministry of Health (“MoH”) in Indonesia last year. The submission and all discussions with MoH were conducted on Firebrick’s behalf by an Indonesian company, PT Pyridam Farma Tbk (“**Pyridam**” or “**PYFA**”) and its affiliate import agent, PT Mursmedic, acting as regulatory agents for Firebrick.

Under the Product Registration Services Agreement (“**Agreement**”) with Pyridam, Firebrick can now utilise the Nasodine approval and commence importation and distribution of Nasodine Nasal Spray in Indonesia. Specific terms of the Agreement are outlined below.

“As Nasodine’s first regulatory approval, this Indonesian approval is a pivotal event for Firebrick,” said Execution Chairman, Dr Peter Molloy. “Given that Indonesia has a population of 285 million and is the largest market in Southeast Asia, this approval is also a massive value inflection point for Firebrick.”

Before importation, distribution and sales of Nasodine can commence, Firebrick will need to manufacture the product in local language packaging and importantly, Firebrick will need to secure a local marketing partner. The latter will be a priority project for Firebrick’s new Head of Business Development and Licensing (see announcement 17 March 2026).

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

Terms of the Agreement

Parties: The Agreement is between Firebrick Pharma Ltd and PT Pyridam Farma Tbk.

Term: The Agreement has an initial term expiring on 26 June 2030, after which it is renewable by agreement.

Termination: By either Party with 6 months' notice or without notice for cause due to unremedied breach or insolvency.

Services and fees: PYFA provides importation and regulatory services that includes holding, obtaining and maintain regulatory approvals of Nasodine products on behalf of Firebrick, including managing queries and reporting to and from the MoH. Firebrick pays for those services by reimbursement of regulatory filing and annual maintenance fees. PYFA also receives an Importation Assistance Fee of 4% of the invoice value of all orders. There are no commitments to any minimum sale orders of Nasodine contained within the Agreement.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines. Nasodine® Throat Spray is the first follow-on product, now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and plans to expand sales to up to 10 markets over three years, including the Philippines. For further information, visit <https://nasodine-sg.com/>

Contacts:

Media contact:

Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:

Kam Watson, Firebrick Pharma
investors@firebrickpharma.com